Figure 1.
Types and causes of ITP among patients undergoing splenectomy. The large pie chart (top left) illustrates the overall distribution of ITP types in the cohort (N = 88), with primary ITP comprising 75% and secondary ITP 25% of cases. The 2 smaller pie charts (bottom left) show the proportion of postsplenectomy TPO-RA use within each ITP type: 44% of patients with primary ITP and 36% of those with secondary ITP received TPO-RA after splenectomy. The bar chart (right) outlines the underlying causes of secondary ITP, with lymphoproliferative neoplasms (predominantly indolent lymphoma) being the most common. Indolent lymphomas included CLL, LPL, MZL, and FL, whereas aggressive subtypes included HL and DLBCL. One patient with HL also had hepatitis C infection. Among autoimmune causes, SLE was most frequent, with 1 cause attributed to APLS. APLS, antiphospholipid antibody syndrome; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; LPL, lymphoplasmacytic lymphoma; MZL, marginal zone lymphoma; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

Types and causes of ITP among patients undergoing splenectomy. The large pie chart (top left) illustrates the overall distribution of ITP types in the cohort (N = 88), with primary ITP comprising 75% and secondary ITP 25% of cases. The 2 smaller pie charts (bottom left) show the proportion of postsplenectomy TPO-RA use within each ITP type: 44% of patients with primary ITP and 36% of those with secondary ITP received TPO-RA after splenectomy. The bar chart (right) outlines the underlying causes of secondary ITP, with lymphoproliferative neoplasms (predominantly indolent lymphoma) being the most common. Indolent lymphomas included CLL, LPL, MZL, and FL, whereas aggressive subtypes included HL and DLBCL. One patient with HL also had hepatitis C infection. Among autoimmune causes, SLE was most frequent, with 1 cause attributed to APLS. APLS, antiphospholipid antibody syndrome; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; LPL, lymphoplasmacytic lymphoma; MZL, marginal zone lymphoma; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

or Create an Account

Close Modal
Close Modal